tetano
Editor, Senior Moderator
J Med Virol
. 2020 Sep 25.
doi: 10.1002/jmv.26554. Online ahead of print.
Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme? a medical device mouth spray against common cold
?g?sta Gudmundsdottir[SUP] 1 2 [/SUP], Reynir Scheving[SUP] 2 [/SUP], Fredrik Lindberg[SUP] 3 4 [/SUP], Bjarki Stefansson[SUP] 2 [/SUP]
Affiliations
Abstract
Background: The COVID-19 pandemic calls for effective and safe treatments. SARS-CoV-2 causing COVID-19 actively replicates in the throat, unlike SARS-CoV, and shows high pharyngeal viral shedding even in patients with mild symptoms of the disease. HCoV-229E is one of four coronaviruses causing the common cold. In this study, the efficacy of ColdZyme? (CZ-MD), a medical device mouth spray, was tested against SARS-CoV-2 and HCoV-229E in vitro. The CZ-MD provides a protective glycerol barrier containing cod trypsin as an ancillary component. Combined, these ingredients can inactivate common cold viruses in the throat and mouth. The CZ-MD is believed to act on the viral surface proteins that would perturb their entry pathway into cells. The efficacy and safety of the CZ-MD has been demonstrated in clinical trials on the common cold.
Method of study: The ability of the CZ-MD to inactivate SARS-CoV-2 and HCoV-229E was tested using an in vitro virucidal suspension test (ASTM E1052).
Results: CZ-MD inactivated SARS-CoV-2 by 98.3% and HCoV-229E by 99.9%.
Conclusion: CZ-MD mouth spray can inactivate the respiratory coronaviruses SARS-CoV-2 and HCoV-229E in vitro. Although the in vitro results presented cannot be directly translated into clinical efficacy, the study indicates that CZ-MD might offer a protective barrier against SARS-CoV-2 and a decreased risk of COVID-19 transmission. This article is protected by copyright. All rights reserved.
Keywords: Coronavirus; cell cultures; microbial cultures; respiratory tract.
. 2020 Sep 25.
doi: 10.1002/jmv.26554. Online ahead of print.
Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme? a medical device mouth spray against common cold
?g?sta Gudmundsdottir[SUP] 1 2 [/SUP], Reynir Scheving[SUP] 2 [/SUP], Fredrik Lindberg[SUP] 3 4 [/SUP], Bjarki Stefansson[SUP] 2 [/SUP]
Affiliations
- PMID: 32975843
- DOI: 10.1002/jmv.26554
Abstract
Background: The COVID-19 pandemic calls for effective and safe treatments. SARS-CoV-2 causing COVID-19 actively replicates in the throat, unlike SARS-CoV, and shows high pharyngeal viral shedding even in patients with mild symptoms of the disease. HCoV-229E is one of four coronaviruses causing the common cold. In this study, the efficacy of ColdZyme? (CZ-MD), a medical device mouth spray, was tested against SARS-CoV-2 and HCoV-229E in vitro. The CZ-MD provides a protective glycerol barrier containing cod trypsin as an ancillary component. Combined, these ingredients can inactivate common cold viruses in the throat and mouth. The CZ-MD is believed to act on the viral surface proteins that would perturb their entry pathway into cells. The efficacy and safety of the CZ-MD has been demonstrated in clinical trials on the common cold.
Method of study: The ability of the CZ-MD to inactivate SARS-CoV-2 and HCoV-229E was tested using an in vitro virucidal suspension test (ASTM E1052).
Results: CZ-MD inactivated SARS-CoV-2 by 98.3% and HCoV-229E by 99.9%.
Conclusion: CZ-MD mouth spray can inactivate the respiratory coronaviruses SARS-CoV-2 and HCoV-229E in vitro. Although the in vitro results presented cannot be directly translated into clinical efficacy, the study indicates that CZ-MD might offer a protective barrier against SARS-CoV-2 and a decreased risk of COVID-19 transmission. This article is protected by copyright. All rights reserved.
Keywords: Coronavirus; cell cultures; microbial cultures; respiratory tract.